4.8 Article

Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 5, Pages 1644-1652

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI61429

Keywords

-

Funding

  1. NIH [R21 AI080364, R01 A150529, R01 A158715, P30 Al27767]
  2. Yerkes Regional Primate Research Center [RR000165]
  3. Bristol Myers Freedom
  4. Deutsche Forschungsgemeinschaft

Ask authors/readers for more resources

SIVs infecting wild-living apes in west central Africa have crossed the species barrier to humans on at least four different occasions, one of which spawned the AIDS pandemic. Although the chimpanzee precursor of pandemic HIV-1 strains must have been able to infect humans, the capacity of SIVcpz strains to replicate in human lymphoid tissues (HLTs) is not known. Here, we show that SIVcpz strains from two chimpanzee subspecies are capable of replicating in human tonsillary explant cultures, albeit only at low titers. However, SIVcpz replication in HLT was significantly improved after introduction of a previously identified human-specific adaptation at position 30 in the viral Gag matrix protein. An Arg or Lys at this position significantly increased SIVcpz replication in HLT, while the same mutation reduced viral replication in chimpanzee-derived CD4(+) T cells. Thus, naturally occurring SIVcpz strains are capable of infecting HLTs, the major site of HIV-1 replication in vivo. However, efficient replication requires the acquisition of a host-specific adaptation in the viral matrix protein. These results identify Gag matrix as a major determinant of SIVcpz replication fitness in humans and suggest a critical role in the emergence of HIV/AIDS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available